Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Exenatide (AC2993) in Type 2 Diabetes
NCT01789957Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2002
- Primary completion
- Jun 2004
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Primary endpoints: Change in HbA1c at 52 weeks, Change in body weight at 52 weeks and 1 more. Started Sep 2002; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01789957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01789957.